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Purpose: Staphylococcus aureus carriage poses an increased risk of S. aureus infection. The
aim of this study was to investigate the colonization of S. aureus among healthy individuals
and to establish a prospective cohort and biobank for research in the health consequences of
colonization.
Population and methods: The Danish Blood Donor S. aureus Carriage Study (DBDSaCS)
was established in 2014. So far, a total of 6082 healthy participants have been included with
nasal swabs and repeated swabs are performed at subsequent donations. Samples from the
ﬁrst 2217 participants were cultured using a two-step method to evaluate the effect of using
enrichment broth. Furthermore, 262 participants were sampled from both the nares and the
throat. All participants completed a questionnaire with self-reported health, anthropometric
measurements, current smoking status, and physical activity. Plasma samples, nasal swab
transport media, and S. aureus isolates were stored.
Results: The prevalence of S. aureus nasal colonization was 41%. The prevalence of
colonization was higher in men (46%) than women (34%), lower for smokers, and decreased
with increasing age (<25 years: 44% vs >55 years: 35%). In participants swabbed from the
nose and throat, the prevalence of S. aureus colonization after enrichment was 55% with
signiﬁcantly higher prevalence in the throat (45%) than in the nose (40%). The use of an
enrichment broth increased the proportion of S. aureus colonization.
Conclusion: We describe a large and growing cohort of healthy individuals established to
investigate predictors for S. aureus carriage and the health consequences of carriage.
Multiple projects using data from DBDSaCS linked with Danish health registers, biomarkers,
and genetic markers are ongoing. Results will be published in the coming years.
Keywords: prospective cohort study, Staphylococcus aureus, colonization, epidemiology,
blood donor health, risk factors
Introduction
The aim of the Danish Blood Donor Staphylococcus aureus Carriage Study
(DBDSaCS) established in 2014 is to investigate the colonization of S. aureus
among healthy individuals and to establish a prospective cohort and biobank for
research purposes. The DBDSaCS originates from the Danish Blood Donor Study
(DBDS, www.dbds.dk).1 The DBDSaCS is unique allowing investigation of the
mechanisms involved in S. aureus carriage and the inﬂuence of carriage on health
and the risk of disease among otherwise healthy individuals.
S. aureus is a bacterium that colonizes the skin and mucous membranes of
humans and animals; up to 50% of the healthy adult population are carriers of S.
aureus in the nose either intermittently or persistently.2,3 The anterior nares are
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believed to be the most important colonization site for S.
aureus.4–6 However, several studies have highlighted the
importance of throat colonization, as throat carriage fre-
quency has been reported to range between 30% and
47%.7–9 Rapid diagnostic tests are often used to determine
S. aureus carriage because molecular diagnostic methods,
when compared to culture methods, can reduce the “turn-
around time” in the laboratory and, in the case of methicil-
lin-resistant S. aureus (MRSA), reduce costs by avoiding
any unnecessary isolation days.10 However, culture methods
remain highly important as molecular tests have been
shown to produce both false-negative and false-positive
results.11,12 Culture methods are furthermore less expensive
and central for susceptibility testing and surveillance.
Apart from being a commensal in the nasal and throat
cavity, S. aureus is also a potent pathogen which may
cause a variety of diseases, ranging from simple skin
infections to life-threatening soft tissue infections, deep
abscesses, arthritis, osteomyelitis, endocarditis, and
bacteremia.13 S. aureus is a dominant nosocomial patho-
gen in both community and health care settings
worldwide.14,15 Moreover, S. aureus is the second most
frequent pathogen in bloodstream infections in Denmark
and accounted for 18% of all bloodstream infections in
2017 (www.danmap.org).16 Invasive S. aureus infections
are associated with a high morbidity and mortality, and
although colonization itself is harmless, carriers are at
increased risk of infection.2,3,17–21 In case of resistance
toward various antibiotics, such as in MRSA which is
resistant to most of the beta-lactam group of antibiotics
complicates treatment of S. aureus infections and consti-
tute an increasing burden on health care resources.15,22
Hence, knowledge of S. aureus carriage and effective
measures to prevent S. aureus infections are important.
The mechanisms involved in the transition from car-
riage to infection are not completely understood but infec-
tion is probably a result of both bacterial and host
factors.23,24 The causal relation between S. aureus nasal
carriage and infection is supported by the fact that deco-
lonization of the nose by nasal application of mupirocin
among carriers of S. aureus prior to surgery reduces the
risk of subsequent infection.25,26 However, the effect of
nasal carriage among healthy individuals on the risk of
subsequent infection is not known and therefore there is a
need for a population-based study addressing this.
There are only a few population-based cohort studies on
S. aureus colonization. The Tromso Staf and Skin Study in
Norway,27,28 The Study of Health in Pomerania in
Germany,29 and the Generation R Study in The
Netherlands30 are all examples of sound population-based
studies that have addressed S. aureus colonization and deter-
minants for S. aureus colonization. However, the DBDSaCS
is unique because participants are healthy blood donors, a
selected group which is generally healthier than the back-
ground population, because they must comply with strict
criteria to be blood donors. Furthermore, we can assess out-
comes in the Danish health registers allowing for complete
follow-up with regard to diagnosis codes among both inpa-
tient and outpatient hospital contacts as well as redeemed
prescriptions, also after the participants have seized to donate
blood. Our participants will be followed for 25 years.
Furthermore, genotyping of all participants in the
DBDSaCS for more than 650,000 single-nucleotide poly-
morphisms (SNP) is ongoing. This provides exceptional pos-
sibilities in the future investigation of host factors as
determinants for S. aureus colonization in addition to addres-
sing bacterial colonization determinants. The DBDSaCS
allows us to investigate themechanisms involved in S. aureus
carriage and the inﬂuence of carriage on health and the risk of
disease.
Here, we describe the setting, organization, and content
and present the cohort and results of colonization for
quality assurance from the ﬁrst 6082 participants.
Objectives
The overall aim of the DBDSaCs is to establish a prospec-
tive cohort and biobank to investigate the epidemiology,
predictors, underlying mechanisms, and associated risk
factors of S. aureus nasal colonization/carriage and to
examine the effect of S. aureus nasal carriage on health
outcomes. Speciﬁcally, the objectives of the DBDSaCS
can be categorized as follows:
1. To determine the prevalence of S. aureus nasal car-
riage among healthy adults and to examine whether
carriage is associated with demographic factors
2. To identify genetic and immunological predictors
and risk factors for S. aureus nasal carriage
3. To investigate whether S. aureus carriage is asso-
ciated with inﬂammatory and endocrine markers in
serum or plasma
4. To examine the impact of S. aureus carriage in
healthy individuals on the risk of subsequent disease
5. To examine the nasal microbiome among healthy adults
and whether genetic or demographic factors are asso-
ciated with the composition of microorganisms
Erikstrup et al Dovepress
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Study population and setting
The DBDSaCS is an ongoing multicenter, multiregional,
prospective cohort of blood donors. Our study was
initiated in January 2014 at Aarhus University Hospital
in collaboration between the Department of Clinical
Immunology and Department of Clinical Microbiology.
The DBDSaCS has recruited participants among parti-
cipants in the Danish Blood Donor Study (DBDS) at
multiple blood donation facilities in the Central Denmark
Region from January 2014 and from September 2014 in
the North Denmark Region. DBDSaCS will include parti-
cipants from the Zealand Region from August 2019. The
DBDS is an ongoing nationwide, public-health study and
biobank launched 1 March 2010 (www.dbds.dk). So far,
more than 125,000 donors from all ﬁve administrative
regions of Denmark have been included. Blood donors
aged from 18 to 67 years (70 years from 1 January
2019) are invited to participate. EDTA plasma samples
from each donation and whole blood for DNA puriﬁcation
are stored in a biobank. Participants have consented in
merging study data with data from public registers.
Blood donation requires compliance with strict criteria.
Donation is not allowed if the donor received antibiotics
within the preceding 4 weeks. Recent traveling in areas
where malaria can be found (most of Africa, South-East
Asia, and South America) leads to deferral for 6 months
and traveling to areas where ﬂaviviruses are found (most
areas outside of Northern Europe) leads to deferral for
4 weeks. Implicitly, all participants were healthy, nonpreg-
nant, and nonlactating adults testing negative for HIV,
hepatitis B, and C.1,31–33
Blood donors return repeatedly for donation; at the
time of donation, they are asked to participate in the
DBDSaCS and consenting donors complete a question-
naire, a nasal swab is taken by trained health care person-
nel, and plasma samples are stored. Further, 1385
DBDSaCS participants were at subsequent donations
asked to repeat completion of the same questionnaire,
and nasal swab and blood samples were taken again. A
single throat swab concurrent with a nasal swab was
sampled among the ﬁrst 262 participants included in the
study. Only 0.72% declined to participate in the study.
Figure 1 depicts a ﬂowchart of the DBDSaCS cohort
consisting of the following:
● DBDSaCS, Central Denmark Region: 5588 partici-
pants (91.9%) recruited in the donation facility at
Aarhus University Hospital (4989, 82.0%), primarily,
and in the donation facility at Herning-Holstebro
Hospital (599, 9.9%) in the western part of Central
Denmark Region
● DBDSaCS, North Denmark Region: 494 participants
(8.1%) recruited from the blood center of Aalborg
University Hospital.
See Table 1 for characteristics of participants in DBDSaCS
in comparison with blood donors not participating in the
study. We deﬁned nonparticipants as Danish blood donors
donating whole blood or plasma from January 1st 2014 to
April 1st 2019 from the Scandinavian Donations and
Transfusions Database (SCANDAT), a database including
all electronically recorded Danish and Swedish blood
donations since the 1980s and 1970s, respectively. For
characteristics of nonparticipants, one donation from each
donor was randomly sampled as the index donation.
Inclusion of participants is performed year-round
except in July due to reduced capacity. The number of
included participants per calendar month and their carrier
state is presented in Figure 2.
Oral and written informed consent was obtained from
all participants. The DBDSaCS project (1-10-72-307-13)
and the DBDS (M-20090237) were approved by the
Scientiﬁc Ethical Committee in the Central Denmark
Region. The DBDS GWA study was approved by the
Danish National Committee on Health Research Ethics
(1700407). The establishment of the biobank was
approved by the Danish Data Protection Agency (2007-
58-0015). This study was conducted in accordance with
the Declaration of Helsinki.
Microbiological methods
S. aureus colonization was determined by a single nasal
swab taken at study inclusion when participants donated
blood. Until April 2019, 6082 donors have been included.
Samples from the ﬁrst 2217 participants were cultured
using the two-step method. Among the 2217 participants
with samples from the nose and using the two-step
method, 262 participants were also sampled from the
throat.
Samples were taken with sterile Copan ESwabs
(Copan, Brescia, Italy). The samples from the anterior
nares were obtained by a single swab rotated ﬁve times
in both nostrils while applying a gentle pressure. Throat
samples were obtained by rotating a single swab over the
surface of both tonsils and the posterior wall of the
Dovepress Erikstrup et al
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pharynx while applying a gentle pressure. Samples were
stored at +4°C before culturing. Within 24 hrs, all samples
were cultured initially using a two-step method later
replaced by a one-step method.
In the two-step method, the ﬂocked swab (FLOQSwab,
Copan) was ﬁrst streaked on S. aureus chromID agar
plates (SAID) (bioMerieux, Marcy- l’étoile, France) and
then submersed into Tryptase Soy Broth (TSB) (SSI
Diagnostica, Hillerød, Denmark). The SAID plates and
TSB enrichment broths were incubated for 18–24 hrs at
35–37°C. Growth of green colonies on SAID was con-
ﬁrmed as being S. aureus with matrix-assisted laser deso-
rption/ionization time-of-ﬂight mass spectrometer (Bruker
Microﬂex, LT/SH system; Bruker Daltonik GMbH,
Bremen, Germany). From samples without S. aureus
after primary culture, the TSB enrichment broths were
subsequently subcultured on SAID and incubated for
another 18–24 hrs at 35–37°C. S. aureus determination
was performed as described above.
In the one-step culture method, TSB enrichment broth
was inoculated with the ﬂocked swab and incubated for
18–24 hrs at 35–37°C. All samples were subsequently
subcultured from the enrichment broth on SAID and incu-
bated for another 18–24 hrs at 35–37°C; then, S. aureus
determination was performed as described above. The
advantage of the one-step method is a shortening of the
Figure 1 Flowchart of the Danish Blood Donor S. aureus Carriage Study cohort.
Erikstrup et al Dovepress
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cultivation process by 1 day and a reduction of the amount
of plates used.
Data collection and variables
Questionnaires
Participants ﬁlled out a two-page questionnaire with items
including the Short Form-12 (SF-12) health-related quality
of life (HRQL) survey, smoking status, anthropometric
measurements, and physical activity at work and in leisure
time. Questionnaires were double entered. From May 2017,
participants completed the questionnaire electronically at
enrolment as described previously.34 In addition, between
June 2015 and May 2018, a total of 4488 participants in the
DBDSaCS completed a comprehensive electronic question-
naire version 2 in the DBDS; among these, donors com-
pleted questions regarding allergy, asthma, and place of
upbringing (based on standardized questions from the
European Community Respiratory Health Survey question-
naire), hidradenitis suppurativa,35 restless leg syndrome,36
attention deﬁcit hyperactive syndrome, and migraine.37
The SF-12 is an abbreviated version of Short Form-36
(SF-36) developed for population surveys for determining
general health outcomes, described in detail previously.38,39
Brieﬂy, SF-12 consists of 12 items providing a Physical
Component Score and a Mental Component Score, and
these scores explain more than 80% of the variance in the
original eight SF-36 scores,40 higher scores indicating better
HRQL. For missing values in SF-12 items, an imputation
algorithm was used as previously described.38,41
Body mass index (BMI) was calculated as weight divided
by height squared (kg/m2). We categorized each participant
according to BMI using WHO deﬁnitions: BMI <18.5 kg/m2
(underweight), 18.5≤ BMI <25 (normal weight as reference
group), 25≤ BMI <30 (overweight), and BMI ≥30 (obese).42
Table 1 Characteristics of the DBDSaCS cohort (n=6082) in comparison with the national blood donor cohort (n=234,836)
DBDSaCSa Blood donors not participatinga
Women Men Women Men
N (%) 2683 (44.1) 3399 (55.9) 126,738 (54.0) 108,098 (46.0)
Age, years 36.7 (25.7–50.2) 39.1 (28.5–50.9) 34.6 (24.6–48.0) 39.5 (28.0–51.1)
Age strata (%)
18–25 21.6 12.3 26.5 16.8
26–35 26.0 29.3 24.2 24.0
36–45 17.5 21.7 18.9 20.9
46–55 19.2 19.8 18.1 21.3
56–67 15.7 17.0 12.4 17.1
Hemoglobin, mmol/L 8.5 (8.2–8.8) 9.4 (9.1–9.7) 8.5 (8.1–8.8) 9.4 (9.1–9.8)
Donations during previous:
1 year 2 (2–3) 3 (2–4) 2 (1–3) 2 (1–3)
3 years 5 (4–7) 6 (4–9) 3 (1–5) 4 (2–7)
5 years 7 (5–10) 9 (6–12) 4 (2–8) 7 (3–11)
Weight, kg 70 (63–80)b 84 (76–93)b NA NA
Height, cm 170 (165–174)c 183 (178–187)c NA NA
BMI, kg/m2 24.3 (22.1–27.5)d 25.2 (23.3–27.4)d NA NA
Current smoker (%) 11.8e 12.6e NA NA
Short form-12
Physical Component Score 56.6 (53.8–57.8)f 56.6 (54.1–57.9)f NA NA
Mental Component Score 55.1 (51.2–57.7)f 55.8 (52.8–57.7)f NA NA
Notes: Results are reported as medians (interquartile ranges) and numbers (percentages). aThe DBDSaCS cohort includes blood donors from Central Denmark Region and
North Denmark Region compared with blood donors from all ﬁve regions of Denmark not participating. b=49 missing values; cn=87 missing; dn=91 missing; en=46 missing
values; fn=45.
Abbreviations: DBDSaCS, the Danish Blood Donor S. aureus Carriage Study; BMI, body mass index.
Dovepress Erikstrup et al
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Current smokers (yes/no) were deﬁned when answering
either “Yes, but less than 1 cigarette/cheroot/pipe per day”
or “Yes, more than 1 cigarette/cheroot/cigar/pipe per day”
and cumulative tobacco consumption in pack years as
deﬁned elsewhere.38 Physical activity at work and in leisure
time were categorized as high vs low, see the deﬁnition from
the previous study in DBDS.38,43
Biochemical material and measures
Biobank
A biobank with plasma samples (frozen at −20°C), Copan
ESwab transport media, and S. aureus isolates (frozen at
−80°C) was established for the entire cohort. The Copan
ESwab transport media were frozen within 24 hrs after
they were obtained. Our study and biobank serve as a
platform for future research in predictors, underlying
mechanisms, and associated risk factors of S. aureus
nasal carriage, but potentially also for research purposes
on other nasal pathogens. Various biomarkers will be of
interest to measure, including immunological and inﬂam-
matory markers, markers of iron metabolism, and endo-
crine markers (Table 2).
Immunological markers
Erythrocyte and leukocyte subsets were measured with
Sysmex® XT-1800i (Sysmex Corp., Kobe, Japan) on a
blood sample taken prior to blood donation among the
included donors as a part of the daily routine in the Central
Denmark Region Blood Center including: hemoglobin,
hematocrit, mean erythrocyte volume, mean erythrocyte
hemoglobin concentration, white blood cells, platelet counts,
basophil, eosinophil, lymphocyte, monocyte, and neutrophil.
At this point, ferritin measurement is available for 605 parti-
cipants and measurements of remaining participants are
ongoing.
Genetics
A total of 110,000 participants in the DBDS are genotyped for
approximately 650,000 SNPs using the Inﬁnium Global
Screening Array (Illumina Inc., San Diego, CA) in collabora-
tionwith deCODEGenetics (Reykjavik, Iceland). A further >8
million SNPs have been imputed by use of newly sequenced
reference genomes. Standard quality control is applied, thus
variants that fail Hardy–Weinberg equilibrium and samples
with low genotype yield (less than 98%) will be excluded
from the analysis.44 Currently, genetic data on a subgroup of
Figure 2 Bar chart illustrating the number of participants included by calendar month and their carrier status. Orange (or lower pillar) = S. aureus positive; Green (or upper
pillar) = S. aureus negative.
Erikstrup et al Dovepress
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DBDSaCS participants (n=3133) are available. Genetic data
are stored and available for analysis at Computerome
(Technical University of Denmark, Lyngby).
Nasal microbiome
The nasal bacterial density has been measured in 2161
nasal samples using a broad-coverage quantitative poly-
merase chain reaction and the nasal microbiota composi-
tion has been characterized by 16S rRNA gene-based
sequencing. These data are currently being processed.
Registers
In Denmark, the unique personal identiﬁcation number
given to each citizen at birth, immigration, and used in
public registers enables continuous linkage of data of the
entire cohort with the nationwide Danish public registers
hosted by Statistics Denmark (www.dst.dk).
Past and future contacts with hospitals in Denmark are
available through the Danish National Patient Register
(NPR), thus making follow-up of the entire cohort on
development of diseases possible. This register was estab-
lished in 197745,46 and holds records of all hospital contacts
in Denmark with information on dates of admission and
discharge, and diagnostic information based on the
International Classiﬁcation of Diseases, Eighth Revision
(ICD-8) until 1993 and Tenth Revision (ICD-10) from
1994 until present.
Information on redeemed prescriptions from all Danish
pharmacies is available from The Danish National
Prescription Register, which was established in 1994. This
information includes the unique personal identiﬁcation
number of the patient, the type of drug according to the
Anatomical Therapeutic Chemical classiﬁcation system,
dosage, pack size, and the date of redeemed prescription.
Table 2 Samples and data collected in DBDSaCS
No. of samples/
measurements
Material
Baseline plasma samples 12,164 5 mL EDTA plasma from the ﬁrst inclusion in DBDSaCS
Follow-up plasma samples 4180 5 mL EDTA plasma from follow-up in DBDSaCS
Baseline nasal swabs 6082 Nasal swabs from anterior nares, both nostrils
Follow-up nasal swabs, 2nd visit 1385 Nasal swabs from anterior nares, both nostrils
Follow-up nasal swabs, 3rd visit 459 Nasal swabs from anterior nares, both nostrils
Follow-up nasal swabs, 4th visit 165 Nasal swabs from anterior nares, both nostrils
Follow-up nasal swabs, 5th visit 76 Nasal swabs from anterior nares, both nostrils
Throat swabs 262 Throat swabs from oropharynx and both tonsils
S. aureus isolates 3465 S. aureus isolates after culturing from positive nasal and throat swabs
Questionnaire data, DBDSaCS 8067 Anthropometric, health-related quality of life, smoking, and physical activity
data
Questionnaire data, DBDS
version 2
4488 Asthma, allergy, upbringing, and screening questions of hidradenitis
suppurativa
Immunological markers
Complete blood count 7886 Hemoglobin, white blood cells, hemotocrit, platelets,
Leukocyte subsets 6742 Blood cell counts of basophil, eosinophil, lymphocytes,monocytes, and neutrophil
Ferritin 724 Marker of iron metabolism
Genetics 3133 Approx. 650,000 single nucleotide polymorphisms
Nasal microbiome 2161 Nasal microbiome characterization using 16S rRNA gene-based sequencing
Danish registers linkage 6082 Entire cohort linked to NPR, DNPR, and socioeconomic data at Statistics
Denmark
Abbreviations: DBDSaCS, the Danish Blood Donor S. aureus Carriage Study; NPR, the Danish National Patient Register; DNPR, the Danish National Prescription
Register.
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Data informatics, linkage, and
updates
Master data of all participants were recorded in the Danish
blood bank system ProSang 9.1 (CSAM Health, Oslo,
Norway). This system holds records of following main
variables: personal identiﬁcation number, a unique identi-
ﬁcation number for each donation contact, contact infor-
mation, donation history, laboratory test (blood type,
hemoglobin, erythrocyte, and leukocyte subsets), and
screening results (HIV, hepatitis B and C).
Microbiology test results were recorded in MADS
laboratory information system (Dept. of Clinical
Microbiology Aarhus University Hospital, Aarhus,
Denmark) which hold records of following main variables:
personal identiﬁcation number, a unique sample identiﬁca-
tion number, requesting department, date and time of receipt
and answering of samples, anatomical site, microbiological
species, bacteria quantiﬁcation if relevant, and freeze posi-
tions of all nasal swabs and S. aureus isolates.
The DBDSaCS database is stored on a specialized, secure
section of the Danish National Supercomputer–Computerome
(http://www.computerome.dtu.dk). The DBDSaCS database
is updated on a quarterly basis with data exports from
ProSang and MADS. At Computerome, the database is linked
to data from all Danish blood donors (SCANDAT) and to data
from the DBDS currently comprising 125,000 participants.
Linkage to national health registers is already in place and
updates to Denmark Statistics are performed as needed.
Statistics
Characteristics of the cohort are presented as numbers,
percentages, or medians, with interquartile ranges. Groups
were compared by the two-sample T-test for normally dis-
tributed data, χ2 test, or Fisher’s exact test for categorical
data. Correlations between individual characteristics and S.
aureus colonization were evaluated by log-binomial regres-
sion analysis adjusted for age, smoking status, BMI, and
stratiﬁed by sex. Results were reported as risk ratios (RR)
Table 3 Characteristics of the DBDSaCS cohort by carrier status (n=6082)
Total S. aureus-positive S. aureus-negative
N (%) 6082 2488 (41) 3594 (59)
Age, years 38.1 (26.9–50.6) 36.6 (26.5–49.0) 39.3 (27.5–51.3)
18–25 997 (16) 442 (44) 555 (56)
26–35 1693 (28) 729 (43) 964 (57)
36–45 1206 (20) 505 (42) 701 (58)
46–55 1189 (20) 460 (39) 729 (61)
56–67 997 (16) 352 (35) 645 (65)
Women 2683 (44) 924 (34) 1759 (66)
Men 3399 (56) 1564 (46) 1835 (54)
Weight, kga 79 (70–89) 80 (71–90) 78 (69–88)
Height, cmb 177 (170–184) 178 (172–185) 176 (170–183)
BMI, kg/m2 c 24.9 (22.7–27.5) 25.1 (22.9–27.8) 24.8 (22.6–27.2)
BMI, categorized (kg/m2)c
BMI<18.5, underweight (%) 26 (0.4) 12 (0.5) 14 (0.4)
18.5≤BMI<25, normal weight (%) 3064 (51.1) 1191 (48.5) 1873 (53.0)
25≤BMI<30, overweight (%) 2167 (36.2) 899 (36.6) 1268 (35.9)
BMI>30, obese (%) 734 (12.3) 353 (14.4) 381 (10.8)
Current smoker (%)d 739 (12.2) 255 (10.3) 484 (13.6)
Short form-12e
Physical Component Score 56.6 (54.0–57.9) 56.9 (53.8–57.9) 56.6 (54.0–57.9)
Mental Component Score 55.7 (52.3–57.7) 55.7 (52.2–57.7) 55.7 (52.3–57.7)
Notes: Results are reported as medians (interquartile ranges), numbers (percentages). an=49 missing values; bn=87 missing; cn=91 missing; dn=46 missing values; en=45.
Abbreviation: BMI, body mass index.
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with 95% CI. Stata/IC 13.1 (StataCorp LP, College Station,
Texas, USA) was used for statistical analysis.
First results
In April 2019, the cohort comprised 6082 individuals
(Table 3): 44% women and 56% men. The overall pre-
valence of S. aureus nasal colonization was 41% and
colonization was higher in men (46%) than women
(34%) (Table 4). The colonization rates of S. aureus for
the 2217 participants sampled from the anterior nares,
using the two-step method, are shown in Table 5; the
overall prevalence of S. aureus nasal colonization was
34% before and 41% after the use of enrichment broth.
On average, participants colonized with S. aureus in the
nostrils were 1.82 years (95% CI: 1.14–2.51) younger than
noncolonized participants. In both sexes, the prevalence of S.
aureus colonization decreased with increasing age. Thus, the
colonization proportionwas 13percentage points lower among
women aged 55 years or older when compared to women
below 25 years. Similarly, the colonization proportion was 9
percentage points lower among older men (Table 4).
The prevalence of smoking in the cohort was 12.2%:
11.8% for women and 12.6% for men. The prevalence of S.
aureus nasal colonization was 34.2% and 41.7% among smo-
kers and nonsmokers, respectively. Obesity (BMI ≥30 kg/m2)
was more prevalent among S. aureus colonized participants
(14.4%) compared with non-carriers (10.8%) (Tables 3 and 4).
In comparison with the blood donors nationwide not
participating in DBDSaCS, the median age and median
hemoglobin are similar. The DBDSaCS cohort comprises a
larger percentage of men and a smaller age group of 18–25
in return for a larger age group of 26–35. Also, DBDSaCS
participants’ number of donations during the previous 5
years are approximately one and a half-fold higher than
blood donors not participating (Table 1).
The effect of using a two-step culture
method
The effect of using enrichment broth is illustrated in Table 5.
In the 2217 individuals sampled from the nose using the two-
step method, prevalence of S. aureus nasal colonization prior
to and after enrichment was 34% and 41%, respectively.
Enrichment broth increased the number of positive samples
by 21%. The effect of using enrichment broth was higher for
women when compared to men.We found that 8% of women
were only positive after enrichment, corresponding to 24% of
all S. aureus–positive women. In comparison, we found that
6% of men were positive only after enrichment correspond-
ing to 14% of all S. aureus–positive men (Table 5).
In both sexes, there was no difference between indivi-
duals positive for S. aureus after enrichment broth com-
pared to individuals only positive after primary culture
with respect to age, BMI, or smoking status.
The effect of including a throat swab
In the group of 262 participants swabbed in the nose and
the throat, overall prevalence of S. aureus colonization
prior to enrichment was 33% in the nares and 31% in the
throat (Table 6). The combined prevalence of S. aureus
colonization sampled and cultured from the nares and the
throat prior to enrichment was 45%. The combined pre-
valence of S. aureus colonization after enrichment was
55% with a higher prevalence of colonization in the throat
(45%) than in the nose (40%) (Table 6). Enrichment broth
increased the number of S. aureus positive samples from
both nose and throat swabs. However, the effect of using
enrichment broth was more pronounced for throat than for
nose swabs with an additional proportion of positive sam-
ples after enrichment of 43% and 23%, respectively.
Correlation between individual
characteristics and colonization
A characterization of the association between S. aureus
colonization and age, BMI (categorized cf. WHO deﬁni-
tion), and smoking status is presented in Table 7 with
crude and adjusted RRs. In the adjusted model, 10-year
older age was associated with lower risk of S. aureus
colonization among both women (RR=0.87, 95% CI:
0.84–0.91) and men (RR=0.96, CI: 0.93–0.98) and the
inverse association of age on nasal colonization was even
stronger when comparing the oldest (55–67 years) and the
youngest age group (18–25 years) (women: RR =0.66, CI:
0.55–0.79; men: RR=0.80, CI: 0.70–0.92). Similarly, cur-
rent smoking status was associated with lower risk among
both women (RR =0.78, CI: 0.64–0.93) and men
(RR=0.83, CI: 0.73–0.94). Conversely, obesity was asso-
ciated with the risk of S. aureus colonization in both
genders (women: RR=1.22, CI: 1.06–1.41; men:
RR=1.36, CI: 1.22–1.51).
In order to determine long-term S. aureus carriage
status, multiple nasal swabs are collected randomly from
donors returning to donate. A preliminary statement of
carriership among participants with 2–5 samples is pre-
sented in Table S1.
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Discussion
In this cohort of healthy blood donors, we found that the
overall prevalence of S. aureus colonization after enrich-
ment was 41% for nasal carriage and 55% for nasal and/or
throat carriage; men were more frequently colonized than
women. S. aureus colonization was lower among older
participants and smokers, whereas obesity was associated
with an increased risk of colonization. The use of an
enrichment broth increased the proportion of colonization
especially among women and for throat carriage of S.
aureus.
The prevalence of S. aureus nasal carriage in the general
adult population varies according to population, the quality
of sampling, and culture techniques.3,47 In sampling, cul-
ture, and identiﬁcation of S. aureus, all our samples were
cultured within 24 hrs using enrichment broth and a selec-
tive chromogenic media, which lowers the detection limit
for S. aureus. Hence, we found that the overall prevalence
of S. aureus after enrichment was 41%, slightly higher than
the mean S. aureus nasal carriage rate of 37.2% (19.0–
55.1), reported in selected cross-sectional studies of
S. aureus nasal carriage in a review by Kluytman et al.48
Table 6 Prevalence of throat and nasal colonization after primary culture and after enrichment (n=262)
Site of colonization No. % Additional proportion of positive
samples after enrichment (%)
S. aureus-positive in nares 106 40
Before enrichment 86 33
After enrichment 20 8 23
S. aureus-positive in throat 117 45
Before enrichment 82 31
After enrichment 35 13 43
S. aureus-positive in nares and/or throat 144 55
Before enrichment 119 45
After enrichment 25 10 21
Note: Numbers and percentages of samples positive for S. aureus among 262 participants with concomitant nasal and throat swabs.
Abbreviation: No., number.
Table 7 Predictors of Staphylococcus aureus colonization by log-binomial regression analysis (n=6082)a
Characteristics Women Men
Crude model Adjusted model Crude model Adjusted model
Number RR 95% CI RR 95% CI Number RR 95% CI RR 95% CI
Age, 10-year increment 2683 0.88 0.85–0.92 0.87 0.84–0.91 3399 0.97 0.94–0.99 0.96 0.93–0.98
18–25 580 1 1 396 1 1
26–35 697 0.98 0.85–1.12 0.97 0.85–1.11 959 0.91 0.81–1.03 0.90 0.81–0.99
36–45 470 0.77 0.65–0.91 0.75 0.63–0.89 704 0.98 0.87–1.10 0.95 0.84–1.08
46–55 515 0.75 0.63–0.88 0.72 0.61–0.85 653 0.91 0.80–1.03 0.88 0.77–1.00
56-67 421 0.67 0.56–0.81 0.66 0.55–0.79 559 0.83 0.72–0.95 0.80 0.70–0.92
BMI (categorized), kg/m2 b
Normal weight (18.5≤BMI<25) 1464 1 1600 1
Underweight (BMI<18.5) 20 1.02 0.56–1.87 0.96 0.53–1.74 6 1.93 1.34–2.77 1.80 1.25–2.59
Overweight (25≤BMI<30) 775 0.95 0.84–1.08 1.00 0.88–1.13 1392 1.08 0.99–1.17 1.10 1.01–1.19
Obese (BMI≥30) 373 1.15 1.00–1.33 1.22 1.06–1.41 361 1.32 1.19–1.47 1.36 1.22–1.51
Current smokingc
Nonsmoker 2341 1 1 2956 1 1
Smoker 312 0.80 0.66–0.96 0.78 0.64–0.93 427 0.83 0.73–0.94 0.83 0.73–0.94
Notes: Results presented as risk ratios (RR) with 95% CI. aLog-binomial regression analysis of S. aureus colonization with age (10-year age-groups), body mass index (BMI)
categorized cf. WHO deﬁnitions, and current smoking as predictors, stratiﬁed by sex. Crude model = univariate log-binomial regression without adjustment; adjusted model =
based on the crude model with additional adjustment for age, BMI (continuous), and current smoking status. bn=91 missing; cn=46 missing values.
Abbreviation: BMI, body mass index.
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Other explanations for the high prevalence of S. aureus
nasal carriage in our cohort could be the male/female ratio
(men being more frequently culture-positive than
women),49–51 low prevalence of smoking (smokers are
less frequent carriers of S. aureus),50,52 and age distribu-
tion (elderly are less frequently carriers).2 All these asso-
ciations were conﬁrmed in this study.
The S. aureus nasal carriage state can be predicted accu-
rately by the use of quantitative and qualitative results from
two swabs obtained at 1-week intervals.53 In the current
study, the distribution between all positive samples, alternat-
ing samples, and all negative samples is in line with pre-
viously reported prevalences based on repeated nasal swabs
obtained during the study period.2,53,54
We found a signiﬁcantly higher prevalence of S. aureus
carriage among men (46%) than women (34%). Regarding
the lower prevalence of colonization among women, a recent
study by Liu et al using both culture and PCR methods
showed that the difference in S. aureus prevalence between
the culture of samples from women and men was most likely
due to a lower number of S. aureus in the nares of women.55
This is in line with the ﬁndings in the current study where the
effect of using enrichment broth was higher for women than
men. The reason for this is not known, but could be related to
anatomical and gender-dependent differences in the inner
wall of a nostril that includes apocrine sweat glands, sebac-
eous glands, hair follicles, or sex hormones.56
Regarding smoking, we hypothesize that the current
decreasing prevalence of smoking in high-income coun-
tries could be associated with an increase in the prevalence
of S. aureus colonization.
In the current study, S. aureus carriage increased with
obesity. It has previously been reported that obesity was
found to be a predictor for S. aureus nasal colonization,
independent of diabetes, in particular among premenopausal
women.27 Furthermore, in a previous study, we have shown
that obesity among healthy individuals was associated with
an overall increased risk of infection. Obesity was associated
with an increased risk of abscesses, infections of the skin, and
an increased risk of redeemed prescriptions for dicloxacillin
and ﬂucloxacillin.42 We speculate that the higher risk of
S. aureus carriage may contribute to the increased risk of
S. aureus–related infections in obese participants.
Recently, several studies have highlighted the importance
of throat colonization, and throat carriage has been reported
to range between 30% and 47%.7–9,47 In this study, we
included a throat swab from a subpopulation. When using
enrichment broth, the throat was a more common
colonization site than the nose and when combined the pre-
valence of S. aureus in the nose and/or the throat increased to
55%. The use of enrichment broth increased the prevalence,
especially in throat samples, possibly because of a lower
number of S. aureus or sampling difﬁculties in the pharyn-
geal area. Our results conﬁrm that sampling from more than
one anatomical site and using enrichment broth more accu-
rately detects colonization with S. aureus.
Strength and weaknesses
Blood donors are a highly selected, healthy population, sim-
ply because they comply with criteria regarding health status
and lifestyle to be accepted as donors and for their further
activity as blood donors. Also, blood donors are permanently
excluded from blood donation if diagnosed with certain
chronic diseases, including diabetes, hypertension, cancer,
or hypercholesterolemia. This can be both an advantage
and a limitation. Furthermore, persons weighing less than
50 kg cannot be blood donors. Thus, underweight people are
underrepresented in our study. In a socio-demographic
description of blood donors, we found that individuals with
a low educational level (primary and lower secondary educa-
tion) and low incomes are underrepresented in the donor
populations as well as people of non-ethnic Danish origin
and single men.57 Participants in DBDSaCS are similar in
characteristics compared with blood donors not participating
apart from being more actively bled during the previous 5
years before inclusion. This may reﬂect that DBDSaCS
participants are a selected group of blood donors more will-
ing to donate frequently or healthier in order to donate more;
however, these factors do not affect the S. aureus coloniza-
tion rates. We believe that the higher proportion of men in the
DBDSaCS cohort is largely due to women more often being
below the hemoglobin deferral guideline, thus affecting their
possibility being included in DBDSaCS study.
Exclusively sampling from the nose, we miss partici-
pants that are carriers at other sites. However, throat swabs
require more technical skills and results may thus depend on
the skills of different health care workers.8 In DBDSaCS,
participants are included while donating blood and, in this
setting, a nasal swab was more feasible than a throat swab.
Furthermore, exclusively sampling at a single point, we
miss the ability to divide participants into persistent car-
riers, intermittent carriers, and noncarriers. However, this
study already included a second swab for 1385 participants,
and as this study is an ongoing large-scale study, we aim to
include more than 20,000 blood donors. We include
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participants returning for blood donation and collect a sec-
ond nasal swab for a large subgroup within the DBDSaCS.
Conclusion and perspectives
In conclusion, we report that S. aureus nasal colonization rates
among Danish blood donors are in the upper range compared
to previous European population–based studies. Using an
enrichment broth increased the detection rate of S. aureus
carriers and the effect was more pronounced for throat swabs
and among women. Our ﬁndings support previously reported
prevalences of S. aureus carriage types and determinants of S.
aureus colonization, including smoking and aging that are
inversely associated with colonization while male sex and
obesity are positively associated with colonization. This
underscores that the DBDSaCS is a feasible platform for
future S. aureus carriage studies. Our study is unique as it
includes only healthy blood donors complying with strict
criteria to be allowed to donate blood. This minimizes effects
from existing diseases and recent antibiotic treatment as
impacting on the risk of both S. aureus carriage and subse-
quent infection. The participants are followed through the
Danish national health registers with complete follow-up
regarding contacts to hospitals and redeemed prescriptions.
We will therefore over time be able to assess the impact of S.
aureus carriage on the health of the participants. A number of
projects using DBDSaCS data, as described above, have
already been initiated in order to fulﬁll the primary objectives.
Speciﬁcally, a follow-up study assessing the association
between S. aureus nasal and/or throat carriage and the risk of
infection with S. aureus or other infections is scheduled in
spring 2020. Further, the association of carriage on, eg, dia-
betes, cardiovascular, and autoimmune diseases, will be
addressed in future studies. The ﬁndings will be published in
the years to comewith the ﬁrst publications being submitted in
2019.
Studying the association between S. aureus and genetic
or environmental predictors may provide unique opportu-
nities to understand key elements of the bacteria and the
diseases that can follow. If an association exists, this
knowledge might facilitate the discovery of new interven-
tions against S. aureus.
Organization
The DBDSaCS is anchored in the DBDS. A growing num-
ber of large-scale population-based studies and epidemiolo-
gical research have been conducted and published using
data from the DBDS cohort. DBDS is managed by a steer-
ing committee and permanent staff capable of conducting
large-scale data collection, analyses, and interpretation in
the general population. In DBDSaCS, the principal investi-
gators are Christian Erikstrup and Lise Tornvig Erikstrup
who leads the coordination of projects and activities, includ-
ing scientiﬁc, ﬁnancial, ethics, and communication tasks.
Also, Christian Erikstrup is a member of the steering com-
mittee in the DBDS making multidisciplinary projects
between the DBDSaCS and the DBDS possible. The steer-
ing committee in DBDSaCS includes Professor Christian
Erikstrup, staff physician Lise Tornvig Erikstrup, PhD fel-
low Khoa Manh Dinh, and Professor Paal Skytt Andersen
with the responsibility of reviewing the scientiﬁc progress.
Further, the steering committee can grant access to data and
biological material based on submitted application accom-
panied by a research proposal that complies with Danish
regulations on ethical approval and data protection.
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